Sionna Therapeutics’ Phase 2 cystic fibrosis program for SION-719 failed to improve outcomes when added to Vertex’s Trikafta, prompting Sionna to stop advancing the add-on approach. The company said the pill delivered no benefit in the trial, and it will discontinue the program while evaluating next steps. Sionna indicated it may take actions to preserve capital, signaling that the setback could lead to workforce reductions. The result removes a potential challenger in the CF market at a time when Trikafta remains the clinical and commercial benchmark. The move also highlights the difficulty of finding incremental benefit on top of highly effective modulators, where endpoints and placebo effects can complicate readouts even for well-designed studies.